Keryx Biopharmaceuticals' Next Price Movers Will Be Trial News

As shares of Keryx Biopharmaceuticals (KERX) dip down towards the $2 mark, it may be a good time to accumulate for the long term; especially if the price of the stock were to dip below the $2 mark.

In the meantime, the company announced on Monday that abstract data from the recently-concluded Phase 2 trial of Zerenex will be presented on October 29th at the American Society of Nephrology (ASN) Renal Week Meeting in San Diego.

The meeting will most likely not impact the KERX share price at all since the data has already been released by the company. The next price movers for KERX, in my opinion, will be news regarding or a start date for the pending Phase III trials.

I'm still accumulating KERX, but I'll pick up the accumulation if we see a price below $2 again during the 'down time'.

Disclosure: VFC is long KERX.

Comments

[KJP712:]

Sounds like a solid gameplan.Will buy on thursday.

Oct 28 07:43 PM

[frorule21:]

Would love to add more. I

Oct 28 08:13 PM

[slimjim2005007:]

Big Jims Fund has been a large buyer here lately, Kerx is headed
over $12 soon or will get bought out.

Oct 29 08:35 PM